FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2015

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

D. Smith
  • Fonction : Auteur
J. Dutel

Domaines

Cancer

Dates et versions

hal-02284989 , version 1 (12-09-2019)

Identifiants

Citer

M. Hebbar, B. Chibaudel, T. André, L. Mineur, D. Smith, et al.. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Annals of Oncology, 2015, 26 (5), pp.1040-1040. ⟨10.1093/annonc/mdv141⟩. ⟨hal-02284989⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More